Considerations for Drug Development in Myelodysplastic Syndromes.
Sekeres MA, Kim N, DeZern AE, Norsworthy KJ, Garcia JS, de Claro RA, Theoret MR, Jen EY, Ehrlich LA, Zeidan AM, Komrokji RS.
Sekeres MA, et al. Among authors: jen ey.
Clin Cancer Res. 2023 Jul 14;29(14):2573-2579. doi: 10.1158/1078-0432.CCR-22-3348.
Clin Cancer Res. 2023.
PMID: 36688922
Free PMC article.